Aptevo Therapeutics Inc.

Company Overview

Aptevo Therapeutics Inc. is a U.S.-based clinical-stage biotechnology company focused on developing novel immunotherapy candidates for the treatment of cancer and hematologic diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on engineered antibody-based therapeutics designed to engage and activate the immune system against malignant cells. Its core technology platform centers on bispecific and multispecific antibody engineering, particularly through its ADAPTIR and ADAPTIR-FLEX technologies, which are intended to improve targeted immune activation while minimizing off-target toxicity.

The company’s primary revenue sources historically have included collaboration agreements, licensing arrangements, and financing activities rather than commercial product sales, as Aptevo remains in the clinical development stage. Its pipeline has focused on acute myeloid leukemia (AML), solid tumors, and other oncology indications. Aptevo was formed in 2016 following the separation of the biotechnology business from Emergent BioSolutions. Since becoming an independent publicly traded company, it has evolved into a specialized immuno-oncology developer with a strategy centered on advancing proprietary biologic candidates through clinical development and strategic partnerships.